Connect with us

Politics

Anti-Marijuana Lawmakers Shut Down By Congressional Committee

Published

on

Marijuana reform advocates scored two victories on Tuesday after a key congressional committee approved a spending bill that included a cannabis banking provision and excluded another rider that previously impeded legalization in the nation’s capital. The moves came in spite of impassioned objections from a handful of Republican lawmakers.

For the first time ever, the House Appropriations Committee passed spending legislation that would provide protections for banks that service marijuana businesses. And a longstanding provision prohibiting Washington, D.C. from using its own local tax dollars to implement a legal cannabis sales system was not included in the bill.

The banking provision states that no funds distributed through the legislation “may be used to penalize a financial institution solely because the institution provides financial services to an entity that is a manufacturer, a producer, or a person that participates in any business or organized activity that involves handling marijuana, marijuana products, or marijuana proceeds” in a jurisdiction where it’s legal.

Rep. Chris Stewart (R-UT) introduced an amendment at the meeting that would have limited the banking protection to the medical cannabis market only, but following extensive pushback from a bipartisan coalition of members, he ultimately withdrew the amendment before forcing a losing vote.

The congressman said that he supports medical cannabis, which voters in his state legalized last year, but felt providing a safeguard for businesses operating in compliance with broader state recreational marijuana laws sends the wrong message from the federal government. He went so far as to say that he didn’t mind if these businesses and their employees are at risk of robberies because they’re operating on a largely cash basis.

“I guess I’m just willing to say a company that’s selling recreational marijuana to our youth and to others, I don’t really care if they have a threat of cash sitting in their basement, if they’re paying their employees in cash,” Stewart said. “I don’t want to make life easier for them. I want to make it more difficult.”

Reps. Mike Quigley (D-IL), Tom Graves (R-GA), Betty McCollum (D-MN), Barbara Lee (D-CA), Brenda Lawrence (D-MI) and David Joyce (R-OH) all voiced opposition to the amendment.

Graves and McCollum argued that excluding the adult-use market from the banking provision would create even more confusion and uncertainty in the financial sector. How would banks be able to differentiate revenue derived from medical versus recreational cannabis sales at shops that sell both, they asked, for example.

“This really isn’t about the issue of medical marijuana and recreational marijuana. The issue is more about states’ rights, quite frankly,” Graves said. “It’s really, really important in my viewpoint that we eliminate some gray space—that we make sure that the rules are defined.”

“It becomes very complicated very fast,” McCollum said of the proposed amendment. “What we want to have is transparency, accountability and confidence in our tax system and our banking system.”

Reps. Harold Rogers (R-KY) and Andy Harris (R-MD) said they supported the amendment, with both focusing on marijuana’s legal status under federal law and warning that approving the provision would encourage more usage.

“Bottom line is what we’re going to do here today is send a message: Is recreational marijuana a thing that the federal government should be promoting?” Harris said.

“There is no state where it’s legal under federal law. It is a gateway drug,” he said. “This is a huge money-making industry. This is Big Cannabis.”

While more financial institutions have been willing to accept cannabis business accounts, many banks still fear being penalized by federal regulators given the lack of clarity on the issue. In 2014, a similar amendment addressing the issue was approved in a House floor vote but it was never enacted into law. The Appropriations Committee rejected a marijuana banking amendment after it was introduced before the panel last year.

Bipartisan legislation that cleared the House Financial Services Committee in March would resolve the problem, but that bill represents a permanent fix whereas this appropriations provision must be annually renewed.

The standalone Secure And Fair Enforcement (SAFE) Banking Act is expected to go before the full House in coming weeks. It currently has 206 cosponsors—nearly half of the chamber.

“Today’s small victories demonstrate an appetite for greater protections of the reform movements progress,” Justin Strekal, political director of NORML, told Marijuana Moment. “Our staying power is undeniable in the effort to end federal prohibition and criminalization.”

Reform advocates secured another victory with the bill’s passage: A provision that has blocked the District of Columbia from spending local taxpayer dollars to legalize and regulate cannabis was excluded from the legislation.

Earlier years’ versions of the bill stipulated that D.C. couldn’t use appropriated funds “to enact any law, rule, or regulation to legalize or otherwise reduce penalties associated with the possession, use, or distribution of any schedule I substance under the Controlled Substances Act or any tetrahydrocannabinols derivative for recreational purposes.”

Voters in Washington, D.C. legalized marijuana possession and cultivation in 2014, but the congressional provision left lawmakers with their hands tied when it came to regulating the plant.

Harris, who first introduced the provision, was expected to introduce an amendment get his language back into the spending legislation during Tuesday’s committee markup, but instead focused on introducing amendments to block the decriminalization of sex work in D.C. and creating regulatory exceptions for private schools in the District, while declining to mention the cannabis provision. The panel rejected both of his D.C. proposals.

“The man who has unapologetically been offering up this rider and fighting for it for years didn’t even bother to introduce the amendment,” said Queen Adesuyi, policy coordinator with the Drug Policy Alliance. “He knew it was going to lose and lose badly. His waving white flag gives us optimism on our ability to secure this win and free D.C. to implement legalization through a racial justice lens the way D.C. residents intended.”

Don Murphy, director of federal policies for the Marijuana Policy Project, told Marijuana Moment that the cannabis rider’s removal from the bill is “a win for the voters of the District, and although it may be low hanging fruit, it sure tastes sweet.”

The appropriations process—which has historically been the only vehicle through which Congress has enacted marijuana policy changes—is being leveraged to address a wide range of cannabis reform proposals this session.

Reports that have been released by the Appropriations Committee this year include calls for medical cannabis research expansion, implementing hemp regulations, establishing regulations for CBD, preventing impaired driving and protecting benefits for military benefits.

On Monday, the panel also published a report urging the federal government to reconsider its employment policies as it concerns federal workers who use cannabis in compliance with state law.

The same day, the House Rules Committee, another powerful panel, cleared an amendment for floor consideration that was introduced by Rep. Alexandria Ocasio-Cortez (D-NY), eliminating a rider prohibiting the use of federal funds for “any activity that promotes the legalization of any drug or other substance in Schedule I.”

The purpose of the legislation is to remove barriers to research into the potential therapeutic use of such substances, including cannabis, psilocybin and MDMA, the congresswoman said.

But the panel declined to advance a separate amendment from Rep. Lou Correa (D-CA) that would have barred the Department of Education from denying or limiting “any funding or assistance to institutions of higher education” where the use or possession of cannabis is permitted.

The committee chairman, Rep. Jim McGovern (D-MA), told Marijuana Moment the amendment wasn’t made in order for procedural reasons and that he will “continue to welcome and encourage debate on marijuana policy.”

The spending bill covering the Treasury Department and funding for Washington, D.C. that was approved the the appropriations panel next heads to the Rules Committee, which will decide which further amendments, potentially including cannabis-related ones, can be considered on the floor.

Congressional Committee Advances Psychedelics Amendment But Blocks Marijuana Proposal

Photo courtesy of Brian Shamblen.

Marijuana Moment is made possible with support from readers. If you rely on our cannabis advocacy journalism to stay informed, please consider a monthly Patreon pledge.

Kyle Jaeger is Marijuana Moment's Sacramento-based senior editor. His work has also appeared in High Times, VICE and attn.

Politics

Kansas Medical Marijuana Hearings Cancelled After Senate GOP Leader Reroutes House-Passed Bill

Published

on

A House-passed bill to legalize medical marijuana in Kansas seems to be in jeopardy, with GOP Senate leadership moving the legislation out of a committee and into a different panel where it may sit in legislative limbo, resulting in the cancellation of hearings that were scheduled to be held this week.

Advocates are concerned about the decision by Senate President Ty Masterson (R), who withdrew the cannabis reform legislation from the Senate Federal and State Affairs Committee days before hearings were to be held on Tuesday and Wednesday. It was then re-referred to the Senate Interstate Cooperation Committee, which Masterson chairs and where the bill’s fate is unclear.

This doesn’t necessarily mean that medical marijuana legalization is off the table for Kansas in 2022, but it does seem to signal that the reform might need to be enacted through another vehicle, either in the legislature or at the ballot, as top Democratic lawmakers in the state are pursuing.

“We certainly hope that this action is just making sure that this bill meets any concerns that Senate leadership may have concerning this historic legislation,” Kevin Caldwell, a legislative manager at Marijuana Policy Project (MPP), told Marijuana Moment. “This bill had widespread bipartisan support in the House last session. We hope Senate President Masterson quickly holds a committee hearing and advances this legislation.”

When the proposal was being advanced in the House last year during the first half of the two-year session, members amended an unrelated bill that previously cleared the Senate to make it the chamber’s vehicle for the policy change. Because of that, it was ruled “materially changed” last May and sent to the Senate for committee consideration.

Now there’s a question of whether lawmakers will be motivated to introduce another separate bill and try to move it through both chambers, requiring another House vote. The Senate president seemed to temper expectations in recent remarks, telling The Kansas City Star that “not a single member” of his caucus has expressed that the issue “was important to them.”

That’s not how Kansas Democrats feel, however. House Minority Leader Tom Sawyer (D) and Assistant Minority Leader Jason Probst (D) said this month that they will be introducing proposals to let voters decide on legalizing medical and adult-use marijuana in the state. At the time, Sawyer said he was “hopeful” that the legislature might separately advance the House-passed legalization measure.


Marijuana Moment is already tracking more than 1,000 cannabis, psychedelics and drug policy bills in state legislatures and Congress this year. Patreon supporters pledging at least $25/month get access to our interactive maps, charts and hearing calendar so they don’t miss any developments.

Learn more about our marijuana bill tracker and become a supporter on Patreon to get access.

“The people of Kansas deserve to know if senators support the overwhelming majority of people who want to alleviate patients’ suffering with a medical cannabis program,” MPP’s Caldwell said. “Now is the time to show compassion to their fellow citizens and vote this bill out of committee.”

“Kansas is one of fourteen states left without a medical cannabis program,” he said. “We have faith that the Kansas Senate will pass this legislation this session and this is just another step in that process.”

Michael Pirner, Masterson’s communications director, told the Star that “medical marijuana legislation is not a priority of Senate leadership,” but did signal the issue may still be considered before the year is over.

“The subject matter has clearly matured and we expect it to be considered at some level this session,” he said. “There are many more pressing topics on the Senate agenda.”

The bill as drafted contains several significant restrictions, including a ban on smokeable cannabis. Members of the Senate Federal and State Affairs Committee did get a briefing on the issue at a meeting last week ahead of the expected, now-cancelled formal hearings before the panel.

Meanwhile, the constitutional amendment that the Democratic leaders are proposing would provide for a more comprehensive program that lawmakers would need to implement.

Gov. Laura Kelly (D), for her part, wants to see medical cannabis legalization enacted, and she said at a briefing with reporters on Friday that she “absolutely” thinks the bill could pass if “everything else doesn’t take up all the oxygen.”

She previously pushed a separate proposal that would legalize medical cannabis and use the resulting revenue to support Medicaid expansion, with Rep. Brandon Woodard (D) filing the measure on the governor’s behalf.

Kelly has she said she wants voters to put pressure on their representatives to get the reform passed.

The governor also said in 2020 that while she wouldn’t personally advocate for adult-use legalization, she wouldn’t rule out signing the reform into law if a reform bill arrived on her desk.

Marijuana Banking Bill Sponsor Says He’s ‘Gonna Get That Darn Thing Passed’ Before Leaving Office

Photo courtesy of Philip Steffan.

Marijuana Moment is made possible with support from readers. If you rely on our cannabis advocacy journalism to stay informed, please consider a monthly Patreon pledge.
Continue Reading

Politics

Marijuana Banking Bill Sponsor Says He’s ‘Gonna Get That Darn Thing Passed’ Before Leaving Office

Published

on

Rep. Ed Perlmutter (D-CO) is retiring from Congress at the end of this session, but he says that he’s going to work to pass his marijuana banking bill before his time on Capitol Hill comes to an end.

The congressman spoke to Colorado Public Radio last week about his decision not to run for reelection this November and his disappointment that, while the House has approved the Secure and Fair Enforcement (SAFE) Banking Act five times now in some form, the Senate has failed to advance it under both Republican and Democratic leadership.

“That one still has me pretty irritated,” Perlmutter said, referring to the fact that Senate Majority Leader Chuck Schumer (D-NY) has effectively blocked his bipartisan legislation. When there was a GOP Senate majority, he was told the bill was “too big and too broad.” Then with a Democratic majority, he’s told that it’s “too narrow and too limited.”

Schumer and his colleagues who are working on a federal legalization bill have repeatedly said that they do not want to see the SAFE Banking Act pass before comprehensive reform is enacted that addresses equity issues. Supporters of the banking bill argue that the incremental policy change is necessary for promote public safety and, importantly, it stands a much stronger chance of getting to the president’s desk with bipartisan support.

Nonetheless, Perlmutter said he plans to spend his remaining months in office pushing to get the job done.

“I have not given up on that one,” he said. “I’m gonna get that darn thing passed this year while I still serve out my term.”

Listen to Perlmutter discuss the marijuana banking legislation, starting around 10:24 into the audio below: 

Asked whether he thinks President Joe Biden would be inclined to sign the measure if it did get to his desk, the congressman said “absolutely.”

“Treasury Secretary [Janet] Yellen is somebody who has been talking to me about this for years,” he said. “I feel very good that it would pass. We’re at 47 states that have some level of marijuana use, all the territories and District of Columbia, and they need to have legitimate banking services.”

“It’s just a no brainer in my opinion,” he said. “And yeah, I’m a little bit irritated, but we’re gonna keep working on it and get it passed this year.”

The last attempt that Perlmutter made to enact the reform was by adding its language to a must-pass defense bill, but it was ultimately sidelined following bicameral negotiations and did not make it into the final version. The congressman told Marijuana Moment last month that he sees other potential vehicles to advance the bill and has spoken with House Speaker Nancy Pelosi (D-CA) about it.

Even some Republicans are scratching their heads about how Democrats have so far failed to pass the modest banking reform with majorities in both chambers and control of the White House. For example, Rep. Rand Paul (R-KY) criticized his Democratic colleagues over the issue last month.

Top Federal Drug Official Says ‘Train Has Left The Station’ On Psychedelics As Reform Movement Spreads

Marijuana Moment is made possible with support from readers. If you rely on our cannabis advocacy journalism to stay informed, please consider a monthly Patreon pledge.
Continue Reading

Politics

Top Federal Drug Official Says ‘Train Has Left The Station’ On Psychedelics As Reform Movement Spreads

Published

on

A top federal drug official says the “train has left the station” on psychedelics.

National Institute on Drug Abuse (NIDA) Director Nora Volkow said people are going to keep using substances such as psilocybin—especially as the reform movement expands and there’s increased attention being drawn to the potential therapeutic benefits—and so researchers and regulators will need to keep up.

The comments came at a psychedelics workshop Volkow’s agency cohosted with the National Institute of Mental Health (NIMH) last week.

The NIDA official said that, to an extent, it’s been overwhelming to address new drug trends in the psychedelics space. But at the same time, she sees “an incredible opportunity to also modify the way that we are doing things.”

“What is it that the [National Institutes of Health] can do to help accelerate research in this field so that we can truly understand what are the potentials, and ultimately the application, of interventions that are bought based on psychedelic drugs?” Volkow said.

The director separately told Marijuana Moment on Friday in an emailed statement that part of the challenge for the agency and researchers is the fact that psychedelics are strictly prohibited as Schedule I drugs under the federal Controlled Substances Act.

“Researchers must obtain a Schedule I registration which, unlike obtaining registrations for Schedule II substances (which include fentanyl, methamphetamine, and cocaine), is administratively challenging and time consuming,” she said. “This process may deter some scientists from conducting research on Schedule I drugs.”

“In response to concerns from researchers, NIDA is involved in interagency discussions to facilitate research on Schedule I substances,” Volkow said, adding that the agency is “pleased” the Drug Enforcement Administration recently announced plans to significantly increase the quota of certain psychedelic drugs to be produced for use in research.

“It will also be important to streamline the process of obtaining Schedule I registrations to further the science on these substances, including examining their therapeutic potential,” she said.

At Thursday’s event, the official talked about how recent, federally funded surveys showed that fewer college-aged adults are drinking alcohol and are instead opting for psychedelics and marijuana. She discussed the findings in an earlier interview with Marijuana Moment as well.

“Let’s learn from history,” she said. “Let’s see what we have learned from the marijuana experience.”

While studies have found that marijuana use among young people has generally remained stable or decreased amid the legalization movement, there has been an increase in cannabis consumption among adults, she said. And “this is likely to happen [with psychedelics] as more and more attention is placed on these psychedelic drugs.”

“I think, to a certain extent, with all the attention that the psychedelic drugs have attracted, the train has left the station and that people are going to start to use it,” Volkow said. “People are going to start to use it whether [the Food and Drug Administration] approves or not.

There are numerous states and localities where psychedelics reform is being explored and pursued both legislatively and through ballot initiative processes.

On Wednesday—during the first part of the two-day federal event that saw nearly 4,000 registrants across 21 time zones—NIMH Director Joshua Gordon stressed that his agency has “been supporting research on psychedelics for some time.”

“We can think of NIMH’s interests in studying psychedelics both in terms of proving that they work and also in terms of demonstrating the mechanism by which they work,” he said. “NIMH has a range of different funding opportunity announcements and other expressions that are priorities aimed at a mechanistic focus and mechanistic approach to drug development.”

Meanwhile, Volkow also made connections between psychedelics and the federal response to the coronavirus pandemic. She said, for example, that survey data showing increased use of psychedelics “may be a way that people are using to try to escape” the situation.

But she also drew a metaphor, saying that just as how the pandemic “forced” federal health officials to accelerate the development and approval of COVID-19 vaccines because of the “urgency of the situation,” one could argue that “actually there is an urgency to bring treatments [such as emerging psychedelic medicines] for people that are suffering from severe mental illness which can be devastating.”

But as Volkow has pointed out, the Schedule I classification of these substances under federal law inhibits such research and development.

The official has also repeatedly highlighted and criticized the racial disparities in drug criminalization enforcement overall.

Delaware Lawmakers File New Marijuana Legalization Bill With Key Equity Revisions

Marijuana Moment is made possible with support from readers. If you rely on our cannabis advocacy journalism to stay informed, please consider a monthly Patreon pledge.
Continue Reading
Advertisement

Marijuana News In Your Inbox

Support Marijuana Moment

Marijuana News In Your Inbox

Marijuana Moment